百奥泰(688177.SH)2025年度归母净亏损3.36亿元

Core Viewpoint - Baotai (688177.SH) reported a revenue of 934 million yuan for the fiscal year 2025, marking a year-on-year increase of 25.64%, while the net profit attributable to the parent company was a loss of 336 million yuan, an improvement from a loss of 510 million yuan in the previous year [1] Group 1: Financial Performance - The company achieved an operating revenue of 934 million yuan in 2025, reflecting a growth of 25.64% compared to the previous year [1] - The net profit attributable to the parent company was a loss of 336 million yuan, which is an improvement from a loss of 510 million yuan in the same period last year [1] Group 2: Revenue Drivers - The increase in revenue is attributed to the company's active market expansion, with sales of Adalimumab injection (Geleli®) and Tocilizumab injection (Shiruili®) steadily increasing compared to the previous year [1] - The company launched Ustekinumab injection (STARJEMZA®) in the United States during the reporting period, contributing to growth in both licensing income and sales revenue [1]